Integrated Quantitative Investments LLC Makes New Investment in Cencora, Inc. $COR

Integrated Quantitative Investments LLC bought a new stake in Cencora, Inc. (NYSE:COR) during the 2nd quarter, HoldingsChannel reports. The fund bought 3,910 shares of the company’s stock, valued at approximately $1,172,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Atlantic Edge Private Wealth Management LLC boosted its position in shares of Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares in the last quarter. Obermeyer Wealth Partners lifted its stake in Cencora by 1.3% during the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock worth $758,000 after purchasing an additional 36 shares during the last quarter. Grove Bank & Trust boosted its holdings in shares of Cencora by 4.3% in the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after purchasing an additional 36 shares in the last quarter. U.S. Capital Wealth Advisors LLC increased its stake in shares of Cencora by 0.4% in the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock valued at $2,563,000 after purchasing an additional 38 shares during the last quarter. Finally, Monument Capital Management raised its holdings in shares of Cencora by 2.4% during the 2nd quarter. Monument Capital Management now owns 1,637 shares of the company’s stock worth $491,000 after buying an additional 38 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on COR shares. Wells Fargo & Company raised their price objective on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Robert W. Baird raised their price target on shares of Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a research report on Thursday, October 30th. UBS Group raised their target price on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Finally, JPMorgan Chase & Co. upped their price target on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $371.09.

Cencora Price Performance

COR stock opened at $361.97 on Friday. The company has a fifty day moving average price of $321.35 and a 200-day moving average price of $302.16. The company has a market capitalization of $70.18 billion, a P/E ratio of 37.24, a PEG ratio of 1.56 and a beta of 0.63. Cencora, Inc. has a 52-week low of $223.92 and a 52-week high of $369.00. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. The company had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. Cencora’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. Cencora’s dividend payout ratio is 30.19%.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 41,544 shares of company stock worth $12,230,941. 10.80% of the stock is owned by insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.